BioCardia is on a fast track to revolutionize heart failure treatment, with major regulatory wins in both Japan and the U.S. The PMDA has endorsed CARDiAmp trial data and outlined clear next steps for approval, while the FDA now sees potential for market clearance based on their ongoing trial — a significant shift from past standards. Their minimally invasive HELIX catheter also received strong feedback. With a patient-focused, cell-based approach and expanding clinical infrastructure, BioCardia is positioning itself to deliver life-changing therapies to those with limited options — especially in Japan where demand is urgent.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
